These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28914644)

  • 21. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
    Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
    Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
    Naderi-Azad S; Sullivan R
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
    [No Abstract]   [Full Text] [Related]  

  • 23. Systemic treatment for BRAF-mutant melanoma: where do we go next?
    Menzies AM; Long GV
    Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2016 Jan; 53():125-34. PubMed ID: 26707829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in malignant melanoma.
    Atkinson V
    Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of systemic therapies in the management of melanoma brain metastases.
    Lyle M; Long GV
    Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
    Margolin K
    Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinatorial approach to treatment of melanoma.
    Ashworth MT; Daud AI
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
    Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
    Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.